Angiotensin II |
| 目录号 GP10023 |
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
-
Purity: >98.00%
- COA (Certificate Of Analysis)
- Datasheet
| Cell experiment: [1] | |
|
Cell lines |
Vascular smooth muscle cells |
|
Preparation method |
The solubility of this peptide in sterile water is >10 mM. Stock solution should be splited and stored at -80°C for several months. |
|
Reaction Conditions |
100 nM, 4 hours |
|
Applications |
Treatment of Angiotensin II caused a large increase in both NADH and NADPH oxidase activity, both in terms of initial rate and peak response. The increase in oxidase activity was not apparent until ~ 1 hour and continued to increase for at least 6 hours. |
| Animal experiment: [2] | |
|
Animal models |
C57BL/6J (apoE–/– ) mice |
|
Dosage form |
Drugs were delivered through the minipumps placed into the subcutaneous space in the back of the neck. 500 or 1000 ng/min/kg for 28 days. |
|
Applications |
Ang II infusion promotes the development of abdominal aortic aneurysms. The region in the abdominal aorta from an Ang II–infused mouse was markedly increased in size. The tissue encompassing this region was resistant to the dissection process typically used to remove adventitial tissue. The bulbous aortic abdominal shape occurred in 20% and 33% of mice in the groups infused with 500 and 1,000 ng/min/kg of Ang II, respectively. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Griendling K K, Minieri C A, Ollerenshaw J D, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circulation research, 1994, 74(6): 1141-1148. [2] Daugherty A, Manning M W, Cassis L A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E–deficient mice. Journal of Clinical Investigation, 2000, 105(11): 1605-1612. |
|
Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung (but also present in endothelial and kidney epithelial cells).
Angiotensin II has been shown to play important roles in mediating hypertension, heart failure, cardiac remodeling, diabetes, and the proliferative and inflammatory responses to arterial injury [1].
Angiotensin II exerts a wide range of effects on the cardiovascular system. It is a potent vasopressor and a powerful stimulus for production and release of aldosterone from the adrenal cortex. It acts via specific receptors in the adrenal glands to stimulate the secretion of aldosterone, which stimulates salt and water reabsorption by the kidneys. Angiotensin increases blood pressure by stimulating the Gq protein in vascular smooth muscle cells (which in turn activates contraction by an IP3-dependent mechanism). It was demonstrated that Ang II activated phospholipase C, resulting in the production of inositol trisphosphate (IP3) and diacylglycerol, which in turn were responsible for the mobilization of [Ca2+]i and the activation of PKC, respectively. Additional studies in SMC cultures examined the properties of Ang II as a growth agonist, in particular its role in promoting cellular hypertrophy, characterized by increases in protein synthesis, cell size, and polyploidy. [2][3]
References:
1. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension. 2001; 38: 1382-1387.
2. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988; 62: 749-756.
3. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989; 13: 305-314.
| Cas No. | 4474-91-3 | SDF | |
| 别名 | Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | ||
| 化学名 | Angiotensin II | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N.CC(=O)O | ||
| 分子式 | C50H71N13O12 | 分子量 | 1046.2 |
| 溶解度 | ≥ 100.2mg/mL in H2O | 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. | ||
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % ddH2O | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。